Also see: Do any supplements or diets help prevent or treat osteoporosis
Add-on to 1-3 oral anti-hyperglycemic agents (metformin, sulfonylurea, or SGLT-2 inhibitor) SURPASS-4 (NCT03730662) was a 104-week open-label trial (52-week primary endpoint) that randomized 2002 adult patients with type 2 diabetes mellitus with increased cardiovascular risk to subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or insulin glargine 100 units/mL once daily (1:1:1:3 ratio) on a background of metformin (95%) and/or sulfonylureas (54%) and/or SGLT2 inhibitors (25%)
KPV is not FDA-approved but is potentially moving toward Category 1 compounding eligibility
NAD+ Injections are part of our broader wellness injections menu offered in-clinic in Arcadia and Beverly Hills with mobile service throughout Los Angeles County
Initiating therapies at a young age, ideally before age 3, leverages neuroplasticitythe brain's ability to reorganize and adapt
Transient increase in heart rate with rapid administration